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S1 
REDESIGNING CANCER THERAPY 
Professor Sir David P. Lane FRS. Dept of Surgery and Molecular Oncology 
Dundee University. 
The completion of the human genome project and a rapidly enhanced 
understanding of the molecular mechanism of human disease are creating a 
wealth of new targets for drug discovery. Keeping pace with this are the 
development of novel technologies that can enhance the speed and accuracy 
of drug discovery at every level of the process. Importantly these 
technologies have a great impact on the cost of drug development enabling 
academic and small Biotech companies to make larger contributions to the 
process. Conversely the recognition of molecular variation in the disease 
process and in the metabolic and toxicological response of individuals to 
therapeutic drugs implies the individualisation of treatment and care that may 
favour the development of a larger number of medicines to treat a particular 
disease. All of these processes are particularly clear in the development of 
new anti-cancer drugs. The Cancer Research Campaign in the UK and the 
NCI in the USA have both instituted schemes that allow academic groups 
access to diverse chemical libraries and high throughput screening against 
validated targets emerging from basic research. Target validation has been 
greatly aided by the development of reporter cell lines, knock out mouse 
derived cell lines and dominant negative mutant and anti-sense approaches. 
Commercially small biotech companies have access to large and diverse 
chemical libraries and success with in silico screening using molecular 
docking software to screen ￿virtual￿ libraries is greatly reducing the number 
of molecules that must be physically tested for activity. This critically 
depends on the increasing rapidity of 3D-structure determination. Exciting 
examples that have emerged from these new approaches include inhibitors 
and activators of the p53 response, signal transduction modifiers and pro-
apoptotic agents. Downstream challenges include more rapid assessment of 
PK, metabolism and toxicology. The new drugs, tailored to specific 
molecular forms of disease, will also pose novel problems for the regulators, 
practitioner and patients.      
S2 
CURRENT INDICATIONS & FUTURE STRATEGIES FOR 
ADJUVANT SYSTEMATIC THERAPY IN EARLY BREAST 
CANCER 
Dr Matti Aapro, Clinique de Genolier, Switzerland 
ABSTRACT NOT RECEIVED 
S3 
CLOSE ENCOUNTERS OF THE MOLECULAR KIND
Malcolm Stevens, Cancer Research UK Experimental Cancer Chemotherapy 
Group, Cancer Research Laboratories, University of Nottingham NG7 2RD 
With the possible exception of taxol and combrestestatin anticancer drugs 
don’t grow on trees.  Rather they have ’emerged’, usually following the initial 
efforts of chemists, and have been subjected to chemical, pharmacological 
and pharmaceutical evolutionary forces which have weeded out the unfitted 
before they are subjected to the ultimate challenge ￿ do they work in the 
clinic, or not?  In the past some of the best agents have secured clinical 
respectability before even their molecular targets have been correctly 
identified.  This approach is perceived by many to be out-dated and its 
practitioners facing, like the dinosaurs, an extinction event.  In the post-
genomics age the modern paradigm envisages drug discovery to be a more 
functional exercise: identification and validation of a molecular target; a hunt 
for new molecules synthesised by combinatorial chemistry; identification of 
’hits’ through high-throughput screening; a honing of lead structures through 
conventional medicinal chemistry; and selection of a clinical candidate.   
Sounds easy doesn’t it?  But now there is a whisper abroad that this process is 
proving cumbersome and impracticable, even before it has chalked up its first 
clinical success.  And what may be perceived as a ’smart’ molecular target 
today may be rendered irrelevant by fast moving biological frontiers 
tomorrow. 
The most precious commodities in drug discovery cancer research, I will 
argue, are novel molecules with novel biological properties, irrespective of 
how they are identified ￿ by high-throughput technologies, chemical 
inquisitiveness, or even trawling the oceans and combing the rain forests.  
Also there has to be a place on the drug discovery landscape for those with 
acute instincts for molecular inventiveness.  The key skills required are 
centred on those Cinderella subjects ￿ the chemical and physical sciences and 
pharmacology ￿ but melded to an in-depth knowledge of breakthroughs in 
cancer biology.  (Keeping up with the literature in all these areas is a 
treadmill indeed!)  Such people will comfortably wear molecules like they 
might do their favourite shirt; their close encounters of the molecular kind 
will have been obtained through a long apprenticeship at the bench; their 
antennae will be attuned to be able to recognise what is a cunning (not 
necessarily stunning) molecule. 
Tom Connors was such a person.  If Cancer Research UK is to achieve its 
mission to discover and develop novel therapeutic products which will 
actually make a difference to the cancer patient, it must identify, nurture (and 
fund) more of his kind. 
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A NOVEL ROLE FOR BRCA1 IN MEDIATING THE INTERFERON 
GAMMA ANTIPROLIFERATIVE RESPONSE
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BRCA1 is a tumour suppressor gene implicated in the predisposition to early 
onset breast and ovarian cancer. We have generated cell lines with inducible 
expression of BRCA1 as a tool to identify downstream transcriptional targets 
that may be important mediators of BRCA1 function. Oligonucleotide array-
based expression profiling identified twelve genes that were up regulated 
following inducible expression of BRCA1. Interestingly the majority of the 
identified targets were previously described interferon regulated genes. 
Northern blot analysis revealed that a subset of the identified targets 
including IRF-7, MxA and ISG-54 were synergistically up regulated by 
BRCA1 in the presence of interferon gamma but not interferon alpha or beta.  
Inducible expression of BRCA1 dramatically enhanced IFN-γ  mediated 
apoptotic cell death suggesting a functionally important role for BRCA1 in 
mediating the IFN-γ  antiproliferative response. In addition, a functional IFN-
γ  pathway was found to be essential for BRCA1 mediated induction of IRF-7 
and MxA. Conversely IFN-γ  mediated induction of IRF-7 and MxA was 
attenuated in the BRCA1 mutant cell line HCC1937. Finally reconstitution of 
the HCC1937 cell line with exogenous BRCA1 restored IFN-γ  mediated 
induction of IRF-7 and MxA in these cells. This study identifies BRCA1 as a 
component of the IFN-γ  regulated signalling pathway and suggest that 
BRCA1 may play a role in the regulation of the IFN-γ  mediated tumour 
surveillance pathway. 
S5 
MARKERS AND MECHANISMS OF ENDOCRINE 
SENSITIVITY/RESISTANCE 
Professor Mitch Dowsett 
Dept. of Biochemistry, Royal Marsden Hospital and Institute of Cancer 
Research, London SW3 6JJ 
A number of hormonal therapies are available for the treatment of breast 
cancer each of which works either by reducing the synthesis of oestrogen or 
by antagonising oestrogen at the oestrogen receptor (ER) in breast 
carcinomas.  Reduced oestrogen synthesis is achieved in pre-menopausal 
women by the ablation of ovarian function. This is achieved medically by the 
application of GnRH agonists. In postmenopausal women GnRH agonists are 
largely ineffective but aromatase inhibitors are an efficacious means of 
treatment.   The ER antagonist tamoxifen also has a degree of oestrogen 
agonist activity which varies between tissues and which may limit its 
therapeutic efficacy.  This mode of action has led to this type of drug being 
renamed a SERM (selective estrogen receptor modulator).  
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carcinomas. ER negativity is the most widely used and reliable marker of de 
novo endocrine resistance.  Of the 80% of patients that are ER positive most 
but not all will show some evidence of response to therapy.  Progesterone 
receptor is an oestrogen-dependent protein and absence of this in ER positive 
tumours indicates a lesser likelihood of response but such tumours have a 
sufficiently good chance of response that this is not a useful indicator of 
resistance.  EGF receptor and HER-2 appear to lead to a degree of resistance 
which may be dependent on the hormonal agent in use: benefit from 
tamoxifen may be reduced in patients that have ER positive HER-2 positive 
tumours and in model systems in which MCF7 human breast cancer cells 
have been transfected with HER-2.  In contrast these cells show continued 
dependence on oestrogen and indeed in some reports hypersensitivity to 
oestrogen. Consistent with this, a recent neoadjuvant (pre-surgical) 
comparative trial found that patients that were ER positive and either HER-2 
positive or EGF receptor positive had a far superior response to letrozole than 
to tamoxifen. Phosphorylation of ER by kinases downstream of these growth 
factor receptors appears to lead to increase sensitivity to the agonist effects of 
tamoxifen and to oestrogen stimulation which results in tamoxifen resistance 
but hypersensitivity to oestrogen deprivation.  
Mechanisms of acquired resistance  to oestrogen deprivation have been 
investigated to a lesser degree than tamoxifen. The major mechanism may be 
by acquired hypersensitivity to the residual levels of oestrogen which occur 
during treatment.  Thus acquired resistance to GnRH agonist in 
premenopausal women may be followed by a second response on the addition 
of an aromatase inhibitor.  These data are recapitulated by in vitro studies in 
which oestrogen deprivation leads to cells which are sensitive to stimulation 
by dosages less than 10
-13M. Mechanisms for this have not been clearly 
delineated but enhanced activity of MAP kinase has been observed and 
differential activation of co-activators may also have influence. 
S6 
KEY ASPECTS OF SURGERY 
Professor David George, Western Infirmary, Glasgow 
ABSTRACT NOT RECEIVED 
S7 
RADIOTHERAPY: CURE AND CO-MORBIDITY
John Yarnold, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT 
The systematic overview of radiotherapy effects in women with early breast 
cancer published by the Early Breast Cancer Trials Collaborative Group in 
May 2000 announced a qualitative change in the rationale of radiotherapy in 
women with early breast cancer. For every 20 isolated local recurrences 
prevented by radiotherapy (&/or by surgery, presumably), there are 5 
additional women alive at 10 years who would otherwise die of breast cancer. 
The only way a local-regional modality can achieve this effect is by the 
prevention of distant metastasis, the dominant cause of breast cancer 
mortality. Assuming cardiac shielding is confirmed by real-time electronic 
portal imaging during radiotherapy all patients, and assuming lymphatic 
radiotherapy is prescribed selectively, iatrogenic cardiac mortality will be 
eliminated and vascular mortality (stroke) minimised. 
The greatest absolute mortality reduction is seen in axillary node positive 
patients, effects that are additive with the local and systemic effects of 
adjuvant systemic therapies. Eradication of axillary lymphatic metastases 
must be a determinant of cure in these patients (absolute reduction in 10-year 
mortality in node positive patients randomised to local-regional radiotherapy 
is 8 - 10%). The survival value of eradicating (by whatever modality) internal 
mammary chain metastases remains to be proven. One thing is certain; 
patients with occult internal mammary chain metastases (30% of axillary 
node positive women) currently have no prospects of cure. 
Who should be prescribed radiotherapy? Patients with ≥  10% risk of local 
recurrence should be offered high quality radiotherapy, thereby preventing 8 
local recurrences and 2 breast cancer deaths at 10 years. This means all 
patients after breast conservation surgery, since there is not sufficient 
evidence for an identifiable group with a local recurrence risk of < 10% at 10 
years. After mastectomy and optimal adjuvant systemic therapy, patients who 
are pN1-3+ also fall into this group, not just the particularly unfavourable 
pN4+ subgroup. Indeed, by restricting post-mastectomy radiotherapy to 
women with 4+ positive lymph nodes (as per the ASCO and St Galen 
consensus statements), there is a risk of throwing the baby (pN1-3+) out with 
the bath water, so to speak. Having eliminated the worst of old radiotherapy 
practices, and shed an unjustified nihilism with respect to local therapy, it is 
high time to implement the curative potential of modern high technology 
radiotherapy. Meanwhile, the UK lags behind other first World countries, 
with waiting lists of several months for curative radiotherapy. This is a crazy 
situation, which undermines the proven benefits of early diagnosis and rapid 
access to primary surgery. There can be no doubt that a minority of British 
patients lose their opportunity for cure whilst waiting for treatment. 
S8 
APOPTOSIS AND CARCINOGENESIS: ANALYSING THE 
CONSEQUENCES OF FAILURE TO ENGAGE DEATH PATHWAYS.  
Alan R Clarke, Cardiff University, Cardiff, Wales, UK. CF10 3US  
Loss of the apoptotic response has been implicated in carcinogenesis as a 
consequence of increased survival of DNA-damage bearing cells. We have 
directly tested this inference using  a series of animal models. We have 
previously shown apoptosis to be dependent upon both p53 and the mismatch 
repair (MMR) protein Msh2. We now show that following certain forms of 
damage loss of these pathways translates into increased clonogenic survival 
and increased mutation, but that this is damage and tissue type sensitive. We 
have also analysed mice deficient for Mlh1. Loss of this gene appears less 
detrimental to the apoptotic response when compared to  Msh2 deficiency, 
yet the consequences for mutation frequency and clonogenic survival are 
comparable. Finally, we analysed mice mutant for the methyl binding domain 
protein Mbd4, which has been shown to interact with Mlh1 and function as a 
thymine glycosylase.  Our analysis shows Mbd4 to be essential for the normal 
apoptotic programme following a range of DNA damage and that Mbd4
deficiency can confer increased clonogenic survival in vivo. We now also 
show that Mbd4 deficiency accelerates intestinal tumour development and 
alters the mutation spectrum in mice heterozygous for the Apc
Min allele.  
Taken together our results  demonstrate that  mutations within many genes 
can impact upon the ability to engage apoptosis, however disruption of these 
genes cannot always be directly translated into increased survival, mutation 
and cancer predisposition. 
S9 
THE EMERGING ROLE OF MOLECULAR IMAGING FOR 
EVALUATING CANCER THERAPY 
Brian D. Ross, Alnawaz Rehemtulla, Thomas L. Chenevert & Bradford 
Moffat 
University of Michigan School of Medicine, Center for Molecular Imaging, 
Ann Arbor, MI USA 
The capabilities of magnetic resonance imaging (MRI) and spectroscopy 
(MRS), along with optical imaging techniques such as bioluminescence 
imaging (BLI) for the pre-clinical study of cancer has benefited greatly from 
advances in both hardware and software.  These advances provide exciting 
opportunities to investigate anatomical, cellular and molecular events using 
imaging methodologies.  These opportunities can provide new insights and 
important information related to established, traditional tumor models.   
Additionally, these advances can be applied to emerging therapeutic 
modalities such as cancer gene therapy thus bridging the gap between gene 
delivery, quantitative monitoring of gene expression and correlating this 
expression with therapeutic outcome. 
An overview of the results that have been obtained using MRI/S for studying 
the rat 9L brain tumor model will be given.  MR studies on this well-
established brain tumor model, used for the past 35 years, have yielded a 
wealth of new and vital information.  Through the use of MRI for monitoring 
9L tumor growth and response to therapy, we have observed that the current 
understanding of the effectiveness of traditional chemotherapies such as 
BCNU have been overestimated using traditional methods such as animal 
survival and colony forming assays (using cells obtained from disaggregated 
from solid tumors).  In addition, we have found that cellular changes occur 
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tumor Regression using diffusion-weighted MRI.  This approach may 
provide an important clinical opportunity for individualizing and modifying 
therapeutic protocols during the course of treatment which was recently 
translated into clinical studies. 
The use of MRI/S for quantitative noninvasive evaluation of expression of a 
therapeutic transgene in experimental tumors will also be presented.  In this 
example, stable tumor cell lines expressing the cdna encoding for cytosine 
deaminase (CD) from yeast were grown in animals.  Conversion of the 
nontoxic prodrug 5FC to 5FU by CD and the subsequent conversion to other 
metabolites could be quantitated using MRS.  Finally, BLI was applied to 
both monitoring tumor growth and response to therapy and for following in
vivo gene delivery using an adenoviral vector. 
In conclusion, the use of noninvasive imaging modalities for quantitation of 
therapeutic outcome, gene delivery and monitoring of cellular events is 
emerging as an vital component for translating therapeutic agents from the 
lab into animals and humans. 
S10 
PLASMA EPSTEIN-BARR VIRUS (EBV) DNA AS A TOOL FOR 
POST-TREATMENT MONITORING OF EBV-ASSOCIATED 
MALIGNANCIES 
Y.M. Dennis Lo 
Department of Chemical Pathology, The Chinese University of Hong Kong, 
Prince of Wales Hospital, Shatin, New Territories, Hong Kong 
Recently, much interest has been focused on the presence of nucleic acids of 
tumoral origin in the plasma and serum of cancer patients. Our group has 
used real-time quantitative polymerase chain reaction (PCR) to detect 
Epstein-Barr virus (EBV) DNA in the plasma and serum of patients with 
EBV-associated malignancies. Thus, for nasopharyngeal carcinoma (NPC), 
EBV DNA has been detected in 96% of NPC patients. We have shown that 
circulating EBV DNA concentration is an independent prognostic marker for 
this cancer. Furthermore, plasma EBV DNA has been shown to provide a 
good correlation with clinical events following anti-neoplastic treatment and 
to be predictive of clinical relapse. Apart from NPC, we have also shown that 
EBV DNA can be found in the plasma or serum of patients with other EBV-
associated malignancies, including Hodgkin￿s disease, NK cell lymphoma 
and gastric carcinoma. Serial analysis of samples collected from patients with 
EBV-positive lymphomas also indicates that plasma EBV DNA measurement 
offers a powerful tool for the monitoring and prognostication of some of 
these malignancies. 
S11 
BIOCHIPS IN CANCER RESEARCH: BEYOND cDNA 
MICROARRAYS
Dr Olli Kallioneimi, National Human Genmome Research Insitute, NIH, 
USA 
ABSTRACT NOT RECEIVED 
S12 
A TUMOUR SPECIFIC TARGETED RADIOTHERAPY/GENE 
THERAPY FOR THE TREATMENT OF MALIGNANT DISEASE 
* Dr M Boyd : Department of Radiation Oncology, Cancer Research UK 
Beatson Labs, Garscube Estate, Bearsden Glasgow, G61 1BD. 
Radiotherapy is, after surgery, the most widely used form of cancer treatment 
but the main limitation of radiation treatment is damage to normal tissues. 
This may be overcome by targeted radiotherapy - the selective delivery to 
malignant deposits of cytotoxic radionuclides bound to tumour-seeking 
agents.  We are developing gene transfer techniques, which will allow 
malignant cells to be made more sensitive to radiation or cause them to take 
up radioactive drugs - providing tumour cell kill with reduced damage to 
normal tissues. 
One of the most favourable targeting agents is [
131I]-labelled meta-
iodobenzylguanidine ([
131I]MIBG), which is selectively concentrated in 
neuroblastoma cells bearing the membrane-bound noradrenaline transporter 
(NAT). In an attempt to apply [
131I]MIBG treatment to a range of tumour 
types, we recently introduced the NAT gene into UVW glioma cells, which 
previously did not express NAT.  This resulted in active uptake of 
[
131I]MIBG and cell kill in a dose dependent manner (Boyd et al, 1999, 
2001a). Subsequent studies have indicated that this gene therapy/targeted 
radiotherapy approach may be applicable to the treatment of a range of 
cancers. 
No strategy currently exists for the introduction of transgenes into every cell 
of a tumour in vivo.  Therefore approaches to cancer gene therapy must 
incorporate a component of collateral damage to non-transfected cells.  A 
major advantage of our scheme is the inherent bystander effect afforded by 
radiation cross-fire to non-targeted cells from cells (NAT-expressing) which 
have taken up [
131I]MIBG.  Having developed a novel three-dimensional 
culture system (transfectant mosaic spheroids - TMS) for characterisation of 
the extent of radiation-mediated bystander effects, we showed that when only 
5% of a spheroid mass expresses the NAT transgene, the entire spheroid is 
susceptible to sterilisation by [
131I]MIBG.  Recent experiments conducted 
with Professor Michael Zalutsky, Duke University, indicate that the same 
effect can be achieved using a 700-fold lower dose of the alpha-particle 
emitter [
211At]-astatine conjugated to benzylguanidine (i.e. [
211At]MABG). 
In order to limit NAT transgene expression to tumour cells, we have 
employed, as transcriptional regulators, the human telomerase RNA (hTR) 
and protein component promoters (hTERT) (Boyd et al, 2001b). We are also 
investigating a range of gene delivery vehicles to facilitate clinical 
application of this therapeutic scheme.  One such promising vector is the 
herpes simplex viral variant HSV1716.  This could allow tumour cell kill by 
lysis and, following transgene delivery, targeted radiotherapy. In vitro 
experiments indicate enhanced cytotoxicity to human glioma cells using this 
two-hit scheme 
In summary, this programme of research offers exciting alternatives to 
conventional radiation-based therapies and has the potential for treatment of a 
variety of human malignancies.  
Boyd M, et al., (1999). Gene Therapy, 6:1147;  Boyd M et al., (2001a). J
Gene Medicine   3:  165; Boyd M et al.,  (2001b) Oncogene 20:7804. 
S13 
DESIGN AND EVALUATION OF ANTISENSE 
OLIGONUCLEOTIDES TARGETED AGAINST KIRSTEN RAS IN 
COLON ADENOCARCINOMA CELL LINES
Paul J Ross* 
CRC Centre for Cancer Therapeutics, Institute for Cancer Research and 
Gastroinestinal Unit, Royal Marsden Hospital, Downs Road, Sutton, SM2 
5PT. 
Ki-ras mutations are frequent in colorectal cancers a codon 12 valine 
mutation is the only specific mutation associated with an increased risk of 
recurrence and death.  Antisense oligonucleotide therapy has the potential to 
selectively reduce expression of target genes.  Therefore, the valine codon 12 
Ki-ras mutation was targeted with a series of complimentary 
oligonucleotides.  In a ribonuclease H cleavage assay 5 of a series of 7 
oligonucleotides, cleaved the target RNA with variable efficacy and 
selectivity.  However, none reduced Ki-ras mRNA or protein expression in 
the SW480 colon cancer cell line with the target mutation.  Furthermore, a 
ribozyme targeted against this mutation was weakly active in a cell free 
assay, but had no effect on Ki-ras mRNA expression in SW480 cell lines.  
Computer modelling suggested that the valine codon 12 Ki-ras mutation was 
inaccessible to oligonucleotide hybridisation.  Therefore, an antisense Ki-ras
oligonucleotide was rationally selected by mapping cleavage sites on Ki-ras
exons 1-3 mRNA incubated with a library of random sequence 17-mer 
oligonucleotides and E. coli RNase H.  Three highly accessible regions of Ki-
ras mRNA to oligonucleotides were identified.  Ki-ras mRNA expression 
was variably reduced in the SW480 cell line after transfection with 11 
oligonucleotides complimentary to accessible sites.  The most effective 
oligonucleotide, KR4, reduced Ki-ras mRNA >90% 24 hours after treatment, 
and inhibited Ki-Ras protein expression 48 hours after treatment.  Neither 
cell proliferation, nor cell cycle distribution was significantly different to 
controls.  Vascular endothelial growth factor secretion was reduced to 56% of 
a control oligonucleotide (p<0.001).  KR4 inhibition of Ki-Ras expression 
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Expression profiling by gene array revealed altered expression of a number of 
genes following inhibition of Ki-ras expression. 
KR4 inhibition of Ki-ras in SW480 cells affects factors influencing 
proliferation, vascularisation and metastasis.  This justifies further studies on 
the effect of specifically inhibiting Ki-ras in spheroid growth models and in
vivo.
S14 
STI571: A TYROSINE KINASE INHIBITOR FOR THE TREATMENT 
OF CML ￿ VALIDATING THE PROMISE OF MOLECULARLY 
TARGETED THERAPY
Brian J Druker 
Oregon Health & Science University, Portland, Oregon USA 
STI571 (imatinib mesylate, Gleevec, Glivec) is a rationally designed agent 
that inhibits the tyrosine kinase activity of Bcr-Abl, the causative molecular 
event in chronic myeloid leukemia (CML). STI571 has shown remarkable 
clinical benefits in all phase of the CML and the clinical results with STI571 
will be reviewed. Issues related to clinical trials of molecularly targeted 
agents will be discussed including dose and patient selection. Other issues 
such as why STI571 has been so well tolerated and why cytogenetic 
responses occur will be explored. As relapses have occurred, most commonly 
in advanced phase patients, the mechanisms of relapse will be discussed 
along with possible means to circumvent resistance. STI571 not only inhibits 
the kinase activity of Bcr-Abl, but it also inhibits the c-kit and PDGF receptor 
tyrosine kinases. Other therapeutic targets for STI571, including 
gastrointestinal stromal tumors, which are caused by mutations that activate 
c-kit, will be discussed. These targets will be presented within a framework 
for deciding which tumors might be appropriate to treat with a molecularly 
targeted agent such as STI571. 
S15 
PROGRESS AND CHALLENGES IN THE TREATMENT OF 
ESOPHAGEAL CANCER.  
Arlene A. Forastiere, Johns Hopkins University School of Medicine, 
Department of Oncology, Baltimore, Maryland, U.S.A. 
Over the past two and a half decades there has occurred a striking change in 
the epidemiology of esophageal cancer with over a 350-fold increase in 
annual incidence rates of adenocarcinoma of the distal esophagus and gastro-
esophageal junction in Caucasian males in the United States, Great Britain 
and Scandanavian countries.  At the same time, clinical research efforts have 
resulted in combined modality treatment paradigms for both surgical and 
non-surgical management of  esophageal cancer.  Adenocarcinoma arising in 
the distal esophagus or straddling the G-E junction is distinct from squamous 
cell cancer of the esophagus in patterns of local-regional spread and failure 
but survival rates appear similar.  
In the 1980s, a series of randomized, controlled trials were begun in the US 
evaluating the concurrent administration of chemotherapy and radiotherapy 
(RT) as definitive treatment for disease that had not overtly metastasized to 
distant sites. A landmark trial compared RT alone to RT plus 4 courses of 
cisplatin + 5-fluorouracil (5-FU) chemotherapy in patients with squamous 
cell cancer of the esophagus. A statistically significant improvement in 
median survival, 9 vs 14 mos. and actual 3-year survival, 0 vs 30% was 
demonstrated (Herskovic A et al. 1992; 326:1593). Subsequent efforts to 
improve outcome by intensifying chemotherapy or RT have shown added 
toxicities without therapeutic gain.  Thus, 50 Gy RT and cisplatin + 5-FU is 
today the standard of care for patients with extensive local disease or medical 
conditions that preclude surgery. 
The survival of patients undergoing surgery at major centers is 15-20%.  This 
reflects the advanced stage (IIB or III) of most patients at diagnosis.  To 
improve survival, several combined modality strategies have been 
investigated in randomized, controlled trials.  These include:  preoperative 
chemotherapy, and the combination of preoperative chemotherapy and RT. 
Preoperative cisplatin-based chemotherapy can substantially reduce tumor 
bulk in approximately 50% of patients and in about 5% there will be no 
tumor (path negative) left in the resected esophagus.  Randomized trials 
comparing this strategy to surgery alone show conflicting results but the 
largest trial enrolling 800 patients in the UK showed a 10% survival 
improvement with preop chemotherapy.  The concurrent administration of 
RT and chemotherapy prior to resection takes advantage of the radiation 
enhancing properties of cisplatin and 5-FU. Two-thirds of patients are 
downstaged by this treatment, 25-30% to path negative status. Three 
randomized trials of concurrent chemotherapy and RT followed by surgery 
compared to surgery alone have been reported (Walsh, Urba, Bossett ).   
Consistent findings for patients receiving preop chemo/RT in all studies were 
a 25-28% path negative rate and a 3-year survival rate of 32-36%.  Two trials 
(Walsh, Urba) showed a survival advantage for patients receiving preop 
chemo/RT compared to surgery alone, 32% vs 6% and 32% vs 16%, 
respectively.  These data support combined modality treatment for patients 
with locally advanced, resectable esophageal cancer.   
The challenges ahead include understanding the progression of Barretts 
metaplasia to dysplasia and prevention of adenocarcinoma; and, adding 
molecularly targeted therapies to combined modality treatments to improve 
cure rates in patients with established squamous or adenocarcinoma of the 
esophagus and G-E junction. 
S16 
THE FUTURE CONFIGURATION OF OESOPHAGEAL AND 
GASTRIC CANCER SERVICES - A SURGEON￿S PERSPECTIVE 
Derek Alderson, University Division of Surgery, Bristol Royal Infirmary, 
Bristol BS2 8HW 
NHS Executive guidance has indicated that improvement in outcome of 
patients with oesophageal and gastric cancer in the United Kingdom requires 
changes in service provision.  The most significant change has been the 
creation of cancer networks, each covering approximately two million 
people.  Within each network, it is suggested that specialist oesophagogastric 
teams are created with agreed protocols for patient care and that one or two 
teams within a network should function as cancer centres, at which all 
surgical resections will take place.  The extent to which this might be 
achievable will be strongly influenced by resource allocation to deal 
specifically with these cancers. 
The evidence that centralisation of surgical resources will improve outcomes 
is limited.  Only a single United Kingdom study has carefully studied a large 
group of unselected patients and considered the influence of case mix.   
Decreased mortality was associated with an increased volume of 
operations/surgeon.  The development of large multidisciplinary and 
multiprofessional specialist teams may be difficult to achieve and the 
evolution of surgical practice may still dictate that improved results can be 
obtained with population bases lower than those suggested by the NHS 
Executive.  Reduced working hours for all surgical grades will also have a 
major impact, leading to larger clinical teams and greater concentration of 
care.  On the basis of a minimum number of about 16 - 20 
resections/surgeon/year to achieve and maintain competence, 
oesophagogastric cancer centres will require at least four surgeons.  Concerns 
that operations hitherto carried out in many hospitals could lead to a loss of 
surgical skills and other resources at these institutions, remain unresolved. 
While some changes are inevitable, high quality contemporary audit remains 
fundamental to dictate the speed and extent of change. 
S17 
WHO DOES WHAT, WHERE AND TO WHOM: EVIDENCE FROM 
THE SCOTTISH AUDIT 
Alastair Thompson, Dept of  Surgery & Molecular Oncology, University of 
Dundee, UK 
The Scottish Audit of Gastric and Oesophageal Cancer (SAGOC), the largest 
population based audit of these cancers ever conducted, identified 3293 
patients with cancer of the stomach or oesophagus diagnosed in Scotland 
over a 2 year period.   
The 3293 patients presented to 53 different hospitals; only a third of  patients 
presented initially to a cancer centre. 33% of patients had a delay in 
presentation of >4 months. Endoscopy and biopsy was the primary method of 
diagnosis (in 94% of patients); patients presenting to smaller hospitals had 
Invited Papers
S7
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(Suppl 1), S1–S12significantly less delay in establishing the diagnosis but 22% of patients 
waited > 4 weeks from GP referral.  Staging was predominantly performed 
using CT scanning (in 69% of patients), ultrasound (30%) and laparoscopy 
(20%); those staged using CT with endoscopy or laparoscopy had the best 
outcome. 
1302 patients (39.5%) were treated surgically, 1006 (30.6%) by surgical 
resection, with a 6.5% anastomotic leak rate and 12.9% post-operative 
mortality similar to single centre series reported from the UK. There were no 
statistically significant differences in operation rates, anastomotic leak rates, 
30 day mortality or post operative mortality by size of hospital.   
817 (24.8%) patients received chemotherapy and/or radiotherapy, with 
significant variation by health board ranging from 11% to 36%.  74% of these 
patients waited >  4 weeks for radiotherapy and 58% > 4 weeks for 
chemotherapy. Although toxicity was poorly recorded, 30% of patients had 
grade 3 or 4 toxicity and 3.9% died during therapy.  There were significant 
differences by health board in the delivery of chemotherapy/radiotherapy and 
entry into clinical trials.  948 (28.8%) patients had endoscopic palliative 
therapy with significant variation by health board as to whether stent or laser 
was used; 11.6% of these patients had adverse events and 17% were alive at 1 
year. 
Overall the survival for gastric and oesophageal cancer was 32% (1 year) and 
17% (2 years); patients undergoing surgery had survival of 54% and 33% 
respectively.  Age, co-morbidity, level of physical activity, degree of 
dysphagia, pre-treatment aim of therapy and resection margin involvement 
were the major factors affecting survival. 
SAGOC has demonstrated the extent of the cancer burden, variations in 
practice and adverse outcomes in Scotland.  Sustained fiscal, personnel and 
organisational resource is urgently required to facilitate appropriate guideline 
based management and ongoing audit of an agreed minimum data set for 
these common cancers if improvements in survival are to be achieved. 
S18 
PREOPERATIVE CHEMOTHERAPY IN OESOPHAGEAL AND 
GASTRIC CANCER
David Cunningham, Royal Marsden NHS Trust, Surrey, UK 
The outlook for the small proportion of patients with oesophageal or gastric 
cancer who present with resectable disease is disappointingly poor. 5-year 
survival figures following resection undertaken with curative intent range 
from 20-40%. Oesophago-gastric cancer is relatively sensitive to 
chemotherapy with response rates of 30-40% seen in patients with advanced 
disease. The addition of chemotherapy to surgery, with the intention of 
eliminating microscopic metastatic disease, would appear to be a worthwhile 
strategy to improve survival in this group. Moreover, there are potential 
advantages to preoperative administration. From the practical viewpoint, 
patients are better able to tolerate treatment, surgery may be made easier by 
tumour downsizing and the eradication of distant micrometastatic disease is 
likely to be more successful if dealt with at the earliest possible opportunity. 
There are few large randomised studies looking at the role of pre-operative 
chemotherapy in this setting. A US multi-centre intergroup study randomised 
440 patients to 3 pre-operative and 2 post-operative cycles of cisplatin and 5-
fluorouracil (5-FU) or surgery alone, with no significant difference in 
survival between the 2 groups. Data from the MRC OE0-2 trial, which used a 
similar drug regimen but limited chemotherapy to the pre-operative setting, 
have been recently presented. 802 patients were randomised to surgery alone 
or 2 cycles of pre-operative cisplatin and 5-FU. Overall survival was 
significantly improved in the chemotherapy arm, with 2-year survival figures 
of 45% for chemotherapy and 35% for surgery alone. 87% of chemotherapy 
patients in this trial received 2 cycles of pre-operative therapy, and post-
operative morbidity and mortality rates were not worse in this group. In the 
UK, pre-operative chemotherapy is now regarded as the standard of care for 
patients with operable oesophageal cancer. 
Randomised trials of neo-adjuvant chemotherapy in operable gastric cancer 
have tended to be small, and have yielded conflicting data. A large MRC trial 
￿ the MAGIC trial ￿ randomises patients to surgery alone or surgery plus 3 
cycles of pre-operative and 3 cycles of post-operative ECF (epirubicin, 
cisplatin and infusional 5-FU: one of the most active regimens in advanced 
disease). Accrual is now complete and analysis of the data should provide 
valuable information to help guide future practice. 
S19 
GENE-ENVIRONMENT INTERACTIONS IN GASTRIC CANCER 
Professor Emad M El-Omar, Department of Medicine & Therapeutics, 
Aberdeen University, Aberdeen, Scotland 
Helicobacter pylori infection is associated with divergent clinical outcomes 
that range from simple asymptomatic gastritis to more serious conditions 
such as peptic ulcer disease and gastric cancer. The key determinants of these 
outcomes are the severity and distribution of the H. pylori-induced gastritis. 
Cancer occurs in a gastric milieu characterised by severe inflammation, 
hypochlorhydria and atrophy, all of which precede malignant transformation 
by decades. Host genetic factors are emerging as key determinants of disease 
risk for many cancers. Identifying candidate genes is a major challenge that 
has to stem from a profound understanding of the pathophysiology of the 
disease. In the case of H. pylori-induced gastric cancer, we speculated that 
the candidate genes would influence both gastric physiology and the 
inflammatory response to the infection. We initially targeted the pro-
inflammatory cytokines interleukin-1β  (IL-1β ) and tumour necrosis factor-α
(TNFα ), both of which are inhibitors of acid secretion and key mediators of 
the host￿s response to the infection. We reported that pro-inflammatory 
polymorphisms in the IL-1 gene cluster and the TNF-α  gene (TNF-A)
increase the risk of gastric cancer and its precursors in Caucasian 
populations. Our findings have since been expanded to include other 
candidate genes such as IL-10, and confirmed independently in other 
Caucasian and non-Caucasian populations. In summary, infected subjects 
with a pro-inflammatory host genetic makeup have an increased risk of 
developing severe gastritis, progressive gastric atrophy, hypochlorhydria and 
finally gastric cancer. Other gene-environment interactions clearly influence 
the rate of progression of these lesions and the ultimate malignant 
transformation. 
S20 
HISTONE MODIFICATIONS IN TRANSCRIPTIONAL CONTROL.
Helena Santos Rosa, Sylvain Daujat, Uta-Maria Bauer, Robert Schneider, 
Andy Bannister, Francois Fuks, Paul Hurd and Tony Kouzarides. 
Wellcome/Cancer Research UK Institute, University of Cambridge, Tennis 
Court Road, Cambridge, CB2 1QR, UK. 
Histone modifications are able to regulate transcription positively and 
negatively.  Our ongoing analysis of the mechanism by which such 
modifications regulate transcription has focused on lysine and arginine 
methylation.  Three distinct sites of methylation on histone H3 will be 
discussed, involving residues K4, K9 and R17. 
Methylation at K9 is a repressive event for transcription at both 
heterochromatic sites and at promoters regulated by the RB repressor protein.  
We can now show that K9 methylation is involved in the repression of DNA 
methylated promoters by MeCP2.  A K9 H3 methyltransferase associates 
with MeCP2 and is delivered to the differentially methylated domain of the 
H19 promoter. 
Methylation at K4 results in transcriptional activation.  Using antibodies 
raised specifically against the di- or tri-methylated state of K4, we show that 
only tri-methylated K4 correlates with activation of transcription in yeast.  
This result demonstrates a new rule for histone modifications in which the 
methyl state of a lysine is a consideration for activity.  Given that any lysine 
can be mono-, di- or tri-methylated, the complexity of the code on histones is 
clearly much larger than previously suspected. 
Methylation at R17 correlates with activity of estrogen regulated genes such 
as pS2.  Using chromatin immunoprecipitations we have investigated the 
ordered appearance of modifications on the pS2 promoter following estrogen 
stimulation.  We can show that acetylation by CBP takes place before 
methylation of R17 by CARM1 and that an acetylated H3 substrate augments 
methylation by CARM1.  These results provide evidence for a ￿cross-talk￿ 
between CBP acetylation and CARM1 methylation. 
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TRANSCRIPTION THERAPY FOR CANCER  
Pier Paolo Pandolfi  
Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center.  
Acute promyelocytic leukemia (APL) is characterized by the expansion of 
malignant myeloid cells blocked at the promyelocytic stage of hemopoietic 
development and is invariably associated with reciprocal chromosomal 
translocations always involving Retinoic Acid Receptor α  (RARα ) gene on 
chromosome 17.  RAR variably fuses to PML, PLZF, NPM, NuMA and 
Stat5B genes (hereafter referred to as X genes/proteins).  These translocations 
are balanced and reciprocal, thus leading to the generation of X-RAR and 
RAR-X fusion genes whose products coexist in the APL blast.  The 
invariable involvement in these translocations of RAR, a prototypical 
transcription factor, makes APL a compelling example of aberrant 
transcriptional mechanisms in the etiopathogenesis of cancer.  Here we will 
discuss the recent progresses made in defining the transcriptional basis 
underlying APL pathogenesis and role that the aberrant transcriptional 
activities of X-RAR and RAR-X fusion proteins play in leukemogenesis, 
reviewing the relevant therapeutic implications resulting from this analysis. 
We will address how this new understanding has allowed for the proposal 
and development of novel therapeutic strategies with transcriptionally active 
compounds such as histone deacetylase inhibitors (HDACIs), polyamide 
synthetic transcriptional regulators, and synthetic zinc-finger peptides, which 
are currently being tested in murine leukemia models and in human APL as 
well as in other tumor types.   
S22 
THE MDR1 GENE:  TRANSCRIPTIONAL ACTIVATION AND 
PHARMACOLOGICAL INTERVENTION
K.W. Scotto Fox Chase Cancer Center Philadelphia PA 
Although the basis for anti-cancer drug resistance is multifactorial, the 
overexpression of  P-glycoprotein (Pgp), a membrane protein encoded in 
human cells by the MDR1 gene,  has been causally linked to  the multidrug 
resistant phenotype in a variety of experimental and patient tumors.    Long 
known to confer resistance by mediating the efflux of drugs from the cell, 
more recent studies suggest that overexpression of P-glycoprotein also plays 
a general anti-apoptotic role that extends beyond resistance to 
chemotherapeutics, since cells which overexpress P-glycoprotein are resistant 
to a wide range of caspase-dependent apoptotic inducers, including serum 
starvation, Fas ligand ligation, UV-irradiation and tumor necrosis factor 
(Johnstone RW et. al Cell. 108:153, 2002). 
It has been well established that MDR1 gene expression can be activated by a 
variety of stressful stimuli.  Studies in our laboratory indicate that the signals 
from these divergent stimuli converge on a region of the MDR1 promoter that 
we refer to as the MDR1 enhancesome (Jin, S and Scotto, K.W..  Mol Cell 
Biol.  18:4377, 1998;  Hu, Z et al. J. Biol. Chem.   275:2979, 2000).  This 
region includes binding sites for the trimeric transcription factor NF-Y and 
the Sp family of GC-binding factors.  Together, these DNA-binding proteins 
recruit the histone acetyltransferase PCAF to the MDR1 promoter, resulting 
in the acetylation of promoter-proximal histones and subsequent 
transcriptional activation that is likely mediated by further chromatin 
remodeling.  The potential clinical relevance of this mechanism lies in the 
observation by our laboratory and others that expression of MDR1 is rapidly 
induced in human tumors during the course of chemotherapy.  Thus, the role 
of the MDR1 enhancesome in the regulation of transcription by a variety of 
stimuli makes it an attractive target for therapeutic intervention.   
Ecteinascidin 743 (ET-743) is a tetrahydroisoquinoline isolated from the 
marine organism Ecteinascidia turbinata and presently entering phase III 
clinical trials in the US and Europe.  We have previously shown that ET-743 
interferes with the activation of MDR1 transcription by multiple inducers, 
with minimal effect on constitutive MDR1 expression even after a twenty-
four hour exposure (Jin, S., et.al. Proc. Natl Acad Sci.  97: 6775, 2000).  Our 
studies indicate that ET-743 exerts its effects through the stress-responsive
MDR1 enhancesome complex.  Although the precise mechanism has yet to be 
elucidated, ET-743 does not interfere with the binding of NF-Y or Sp1 to the 
MDR1 promoter, and thus would appear to act subsequent to complex 
binding and promoter-associated chromatin acetylation. Moreover, the effects 
of ET-743 are not restricted to a single class of DNA binding proteins.     
Indeed, ET-743 targets the transcriptional activation of a subset of promoters, 
including those for genes that are activated by the histone deacetylase 
inhibitor TSA. Our current working hypothesis is that ET-743 is a potent and 
novel inhibitor of activated but not constitutive transcription. 
S23 
TRANSLATING CANCER EPIGENETICS INTO CANCER 
THERAPIES
Robert Brown, Cancer Research UK Dept Medical Oncology, Beatson 
Laboratories, Glasgow University, Glasgow, G61 1BD, UK. 
(r.brown@beatson.gla.ac.uk). 
Epigenetic inactivation of genes is as important a driving force as genetic 
inactivation by gene mutation during tumorigenesis. Epigenetic 
transcriptional repression of tumour suppressor genes, cell-cycle genes, DNA 
repair genes and genes involved in invasion and metastasis, have been 
demonstrated in a wide variety of tumour types. Hypermethylated CpG 
islands, often associated with epigenetic silencing, may serve as potential 
markers for diagnosis and prognosis of cancer. CpG methylation of DNA can 
readily be analyzed using methylation specific PCR of candidate genes or 
more global approaches, such as differential methylation hybridization using 
CpG-island microarrays. Methylation patterns of tumour DNA identify 
patient groups with distinct methylation profiles and different clinical 
characteristics.   
There is increasing interest in epigenetic regulation of gene expression for 
new approaches to cancer treatment. For many of the epigenetically silenced 
genes it has been shown that re-expression in tumour cells can lead to 
suppression of cell growth or altered sensitivity to existing anti-cancer 
therapies. Compounds have been identified that can readily reverse 
epigenetic silencing; for instance DNA methyltransferase (DNMT) and 
histone acetyltransferase (HDAC) inhibitors are currently undergoing clinical 
evaluation. Preclinical studies suggest that the combination of DNMT and 
HDAC inhibitors, together with existing therapies, holds particular promise. 
Pharmacodynamic measures of DNA methylation and histone acetylation, as 
well as subsequent effects on gene expression, will help to drive the 
appropriate scheduling of these combinations. Thus the combination of 
epigenomics, to identify those patients who will particularly benefit from 
these types of treatments, together with epigenetic pharmacodynamics will 
allow the full potential of these novel approaches to cancer treatment to be 
examined. 
S24 
HISTONE DEACETYLASE AS A TARGET FOR CANCER 
THERAPY
Nicholas La Thangue
*￿, Robert Brown
￿, Paul Finn and Robert Williams
￿,
*Division of Biochemistry and Molecular Biology, Institute of Biomedical 
and Life Sciences, Davidson Building, University of Glasgow, Glasgow G12 
8QQ. Scotland UK. 
￿Department of Medical Oncology, CR UK Beatson 
Laboratories, Garscube Estate, Switchback Road, Glasgow G61 1BD, 
Scotland UK. and *
￿Prolifix Ltd, 91 Milton Park, Abingdon, Oxfordshire, 
OX14 4RY. England UK. 
In eukaryotic cells the level of histone acetylation plays a vital role in 
chromatin remodelling and the regulation of gene expression.  Histone 
deacetylases (HDACs) are a family of enzymes modulate histone acetylation, 
and the inhibition of HDAC activity has attracted considerable interest as a 
new therapeutic approach for cancer therapy.  Low molecular target weight 
molecules such as trichostatin A (TSA) oxamflatin and suberoylanilide 
hydroxamic acid (SAHA) are potent HDAC inhibitors that block the growth 
of tumour cells. 
Novel chemical series of low molecular weight and synthetically accessible 
inhibitors of HDAC have been designed, and assessed for activity in 
biochemical and tumour cell proliferation assays.  A clinical development 
candidate, PXD101, which inhibits tumour growth by inducing apoptosis, 
was selected for further analysis.  PXD101 blocks the growth in vivo of 
tumour xenografts in mice, with little apparent toxicity.  Most interestingly, 
PXD101 exhibits marked activity in tumour xenografts of cisplatin resistant 
ovarian and tumour cell lines.  Ongoing studies are focussed on 
understanding the spectrum of genes regulated by PXD101 and gaining 
further insights on the sensitivity of tumour cells to HDAC inhibition.  Our 
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in this respect is being rapidly progressed as a viable candidate for clinical 
trials. 
S25 
CANCER SERVICES LEAD THE MODERNISATION OF THE NHS 
Anna Gregor 
Edinburgh Cancer Centre, Edinburgh ,UK 
Over 50 years on - the NHS needs modernising. Cancer services have been in 
the fore- front of interest from public and politicians and clinicians and 
managers are taking the opportunities   to make fundamental changes to the 
design, delivery and monitoring of clinical services in the UK. Many of the 
driving forces are shared across health care systems  and  not specific to 
cancer services. It is because of this generalisibility and because I know them 
best, that I will use examples from the Scottish model. .Survival  outcomes  
have lagged behind most of our Europeans counterparts[1] and the 
differences are real as are the  different resource bases ( financial, 
technological and  availability of professional staff).It is  tempting to 
associate these directly in a causative manner.  UK has insufficient specialist 
capacity and poor scheduling which cause prolongation of treatment 
episodes, anxiety for patients and may worsen outcome.  Fragmented service 
provision, lack of long term strategic planning and political targets distorting 
clinical priorities have led to services developing in a piecemeal and 
opportunistic way with resultant inequalities in provision and access. The 
political risk this represents has brought much needed investment into the 
NHS and cancer services have been major beneficiaries with the caveat that  
tangible improvements are expected in return.  
So what needs to be done to deliver these? To catch up to EU average 
financially may just be possible over the next decade, but shortages of skilled 
manpower, the huge gap in technology infrastructure and the consequences of 
building programme will make this challenging and may not work with 
current models of care .The search for better model has brought: managed 
networks [2], audit and CSBS [3] and service redesign methodology from 
industry [4]. Multidisciplinary working forces examination of roles and 
responsibilities  leading to expanding roles and changing functions [5]. 
Technology, particularly computerisation should facilitate cross 
organisational working but the capacity of the  NHSS  is lagging behind other 
developments. Fundamental to all of this  is the central role of the patient as 
an active partner  and  the quality framework. By putting patients at the 
centre and devolving power over details of decision making   to those 
responsible for  service delivery we will improve experiences and outcomes 
and be able to share learning experiences with other parts of the NHS 
involved in chronic disease management.  
EUROCARE-2, IARC No 151,1999 
MEL (10), 1999 
CSBS reports 2001 
Kerr et al BMJ 2002 
Richardson et al HEALTH policy 45 (2):119-132; 1998 
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FROM SCALPEL TO GENOME.  SAVING LIVES IN COLORECTAL 
CANCER.
Phil Quirke, Academic Unit of Pathology, University of Leeds. 
Can we improve the present 5 year survival in colorectal cancer?  The answer 
is certainly yes and relatively cheaply if current knowledge is taken and 
applied through new initiatives in surgery and pathology. In the future 
molecular pathology offers much hope. 
The evidence for the importance of a high quality total mesorectal excision 
for rectal cancer and obtaining a 1 mm clear pathological circumferential 
margin will be described and the need for the introduction of a quality 
assured national training program for surgeons, pathologists and radiologists 
discussed.  
High quality pathological reporting is important. to identify node positive 
cases and high risk Dukes B cases and work to date on our UK clinical trials 
studies  suggest that pathological factors are the most important factors for 
predicting a poor prognosis. The Royal College of Pathologists national 
minimum dataset should be used routinely as it improves the level of staging 
data available and when used in trials improves the yield of lymph nodes 
which in turn directs adjuvant therapy.   
The translation of the knowledge of the sequencing of the human genome 
into practice offers huge challenges.  Molecular pathological studies may 
identify new prognostic and predictive studies but they should be performed 
in the context of prospective randomized control trials with gold standard 
high quality histopathological data.     Early studies in the UKCCCR AXIS 
study suggest that the preservation of a normal 18q may preserve 
responsiveness to 5FU therapy and that many of the currently fashionable 
markers (microsatellite instability or loss of expression of hMLH1) are not 
helpful for either prognosis or prediction of responsiveness to therapy.   
New technologies are greatly increasing the power of such studies.  cDNA 
arrays are suggesting many new targets for investigation, tissue microarrays 
of hundreds of tumours allow rapid evaluation of these putative markers and 
quantitation of antigen expression by immunocytochemistry and in situ 
hybridization is now feasible.  The use of these technologies will be 
described in current UK colorectal trials.  Programs for the organization and 
distribution of such material and standards for their analysis need to be 
developed to allow rapid assessment of the many putative markers that will 
emerge and their comparison to good pathological and clinical data. 
The funding of a UK quality assured rectal cancer training program would 
improve outcomes in rectal cancer more quickly than at any time over the last 
50 years.  The improving quality of pathological reporting, the major 
advances in new technology and the centrally organized coordination of 
molecular pathology in clinical trials hold hope for further improvements in 
the future. 
S27 
COMPUTATIONAL SIMULATION OF GROWTH FACTOR 
RECEPTOR CLUSTERING 
W.J.Gullick, J.P.Goldman C.G.Johnson
1 and N.L.V.Hayes 
Cancer Biology Laboratory, Department of Biosciences, University of Kent 
at Canterbury, Canterbury, Kent CT2 7NJ and 
1ComputingLaboratory, 
University of Kent at Canterbury, Canterbury, CT2 7NF 
The Epidermal Growth Factor Receptor family consists of four receptors 
(EGFR, c-erbB-2, c-erbB-3 and c-erbB-4) and at least ten ligands. It has been 
proposed that some ligands act principally to form homodimeric receptor 
combinations and others to produce heterodimers. This system is involved in 
control of growth, differentiation, locomotion and death of normal cells and 
has been demonstrated to be one of the main causes of cell transformation in 
many common solid tumour types. 
Much work on this system has used detergent solubilised cells but this 
approach lacks the ability to measure the position of the receptors, ligands 
and second messengers, a factor vital in understanding their interactions. We 
have taken two approaches to analysing the system while retaining this 
information. Firstly we have tagged the EGFR and c-erbB-2 receptors with 
green fluorescent protein and determined their life cycle individually in live 
cells or in combinations using fixed cells and immunofluorescent staining. 
This work has shown that the receptors apparently do not use the same 
mechanisms to reach the cell membrane nor are they always present in the 
same subcellular structures at the same time. 
Second we have constructed a computational simulation of receptor 
interactions (see http://www.cs.ukc.ac.uk/people/staff/cgj/research/receptors. 
html) using object oriented modeling and have displayed the results using 
Java Graphics. In this system the strengths of receptor interactions and the 
degree of ligand occupancy can be varied. The results are displayed 
graphically or can be analysed numerically. This system can be used to 
determine receptor behaviour under different conditions and potentially to 
predict responses and interaction strengths. 
The combination of these approaches should lead to a better understanding of 
the system and to identify sensitive interactions as targets for new inhibitory 
drugs. 
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TARGETS FOR TREATMENT: LESSONS FROM AIDS-RELATED 
MALIGNANCIES
Chris Boshoff, Teenage Cancer Unit, and Cancer Research UK Viral 
Oncology Group, Wolfson Institute for Biomedical Research, University 
College London 
Most cancers that are associated with HIV infection are driven by oncogenic 
viruses, such as Epstein-Barr virus (EBV), Kaposi￿s sarcoma-associated 
herpesvirus (KSHV) and human papillomavirus (HPV). Gaining insight into 
the epidemiology and mechanisms that underlie AIDS-related cancers has 
provided us with a better understanding of cancer immunity and viral 
oncogenesis. 
The increased risk of cancer in immunosuppressed patients after organ 
transplantation, and in patients with inherited defects in immune function, 
such as severe combined immune deficiency, was thought to support the 
immune surveillance hypothesis.  However, immunosuppressed individuals 
are not at an increased risk of developing some of the most common 
malignancies, such as breast, prostate or colon cancer.  Most of the cancers 
that do develop during states of immunodeficiency are rare cancers 
associated with viral infection.  In fact, the risk of developing the most 
common types of epithelial cancers has even been reported to be reduced in 
immunodeficient patients. 
The molecular pathways exploited by the oncogenic viruses, enabling them to 
survive as intracellular parasites and complete successful replication of their 
genomes, are often pathways disrupted in non-viral associated malignancies.  
The cellular responses to viral entry and viral protein expression are similar 
to the cellular countermeasures after activation of protooncogenes, and 
include senescence and/or apoptosis.  KSHV, EBV and HPV have evolved 
counterattacks to these cellular responses including blocking apoptosis by 
interfering with the functions of p53, FAS/CD95/FADD pathway and 
effector caspases; interfering with B-cell signalling (EBV and KSHV) by 
taking over the B-cell antigen-receptor (BCR) signalling pathways, and these 
viruses induce various signal transduction pathways, leading to cell 
proliferation. 
S29 
ANTISENSE AND APOPTOSIS SENSITISATION FOR 
MALIGNANCY
Finbarr E, Cotter. Dept Experimental Haematology, Bart￿s and the London 
School of Medicine, Turner St, London E2 1AD, UK. email;
f.e.cotter@qmul.ac.uk 
Many cancer cells have an inherent resistance to chemotherapy due to the 
abnormal expression of anti-apoptosis genes, such as Bcl-2. The effect is 
mediated through the mitochondrium. The anti-apoptosis proteins maintain 
the the mitochondrial permeability transition pore complex PTPC, spanning 
the membrane, in the closed position, resulting in a block to release of pro-
apototic factors. Antisense oligonucleotides (ASO) complementary to the 
mRNA have the ability to ￿switch off￿ gene expression and have been 
applied to patients with B-cell lymphomas. A phase I study using Bcl-2 ASO 
(G3139, Genta,USA) has been showing evidence of efficacy and acceptable 
toxicity. This study demonstrates evidence of down regulation of the target 
protein in humans by a sequence specific ASO effect. A similar study in 
chronic lymphatic leukaemia (CLL) has shown good efficacy with a dose of 
3mg/kg/day and in vitro studies suggest that a combination with Rituxan (anti 
CD20) improves the response further. This has been followed by a phase II 
study combining Bcl-2 ASO with chemotherapy for a number of different 
types of malignancies including lymphoma, breast cancer, chronic lymphatic 
leukaemia (CLL) , acute myeloid leukaemia and malignant melanoma (with 
high levels of Bcl-2 protein). It has been confirmed that Bcl-2 ASO works 
through a true antisense mechanism and has the ability to ￿open￿ the PTPC. 
Bclxl, another anti-apoptosis gene, is also implicated in cancer 
chemoresistance. An effective ASO has been developed (ISIS, Carlsbad, 
USA) with both in vitro and in vivo efficacy. The Bcl-2 and Bclxl mediation 
of chemoresistance through the mitochondrial PTPC occurs in association 
with the mitochondrial benzodiazepine receptor. Small molecules have been 
developed that act as benzodiazepine receptor ligands, to overcome anti-
apoptosis gene in a similar manner to Bcl-2 ASO to overcome 
chemoresistance. PK11195 is such a molecule. These act on the same 
pathway as the Bcl-2 and Bclxl ASOs and may provide additional therapeutic 
molecules. With care novel therapies based on the biology of the cancer cell 
may help improve the treatment of patients with malignancy.  
S30 
PHARMACOLOGICAL RESTORATION AND PROMOTION OF P53 
TUMOUR SUPPRESSOR ACTIVITY
Barbara Foster and Farzan Rastinejad   Pfizer Global Research and 
Development, Groton, CT USA  
Disruption of the p53 tumor suppressor pathways in virtually all human 
cancers offers a unique opportunity to discover drugs that impact a broad 
range of tumor types.  Drug-like small molecules have been identified that act 
on the isolated DNA binding domain of p53 to specifically promote stability 
of the active p53 conformation.  These compounds can modulate p53 
conformation and transcription activity in cells and in tumors and suppress 
the growth of tumor xenografts with naturally mutated p53.  CP-31398, a 
prototype modulator of p53 conformation, can dramatically improve the 
proapoptotic effects of standard cancer chemotherapy drugs and Trail in 
tumor cells that harbour mutant p53.  Recent data also suggest that CP-31398 
not only restores the tumor suppressor activity of mutant p53, but that it can 
also promote p53 activity in tumor cells that harbour wild-type p53.  Taken 
together, these findings suggest that the conformational stabilization of wild-
type and mutant p53 represents an attractive opportunity to develop a single 
molecular-based therapy, that either alone or in combination with standard 
agents, could be used to treat the vast majority of human malignancies. 
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DT-DIAPHORASE AND PRODRUG ACTIVATION 
Shiuan Chen, Ph.D. 
Div. of Immunology, Beckman Res. Institute of the City of Hope, Duarte CA, 
USA 
DT-diaphorase, also referred to as NQO1 or NAD(P)H: quinone acceptor 
oxidoreductase, is a flavoprotein that reduces quinones and quinonoid 
compounds to hydroquinones, using either NADH or NADPH as the electron 
donor.  It consists of two identical subunits.  Each subunit has a molecular 
weight of 30,000 and contains one FAD prosthetic group, noncovalently 
attached to the protein.  DT-diaphorase is thought to play an important role in 
protecting tissues against the mutagenic, carcinogenic and cytotoxic effects 
of semiquinones that occur widely in nature.  DT-diaphorase catalyzes a two-
electron reduction of quinones, without the formation of semiquinones.  DT-
diaphorase is also known to reductively activate cytotoxic anti-tumor 
quinones such as mitomycins, anthracyclines, and aziridinyl-benzoquinones, 
as well as nitrobenzamides such as CB 1954 [5-(aziridin-1-yl)-2,4-dinitro-
benzamide].  Enzymatic reduction of these anti-tumor compounds gives rise 
to reactive intermediates that can then undergo nucleophilic additions with 
DNA and other macromolecules, suggesting a possible mechanism for their 
cytotoxicity.  A natural mutation of DT-diaphorase, P187S, and an isoenzyme 
of the enzyme, NQO2 (dihydronicotinamide riboside-quinone 
oxidoreductase-2), have been identified.  Their catalytic functions will be 
discussed and compared to those of DT-diaphorase. 
S32 
NITROREDUCTION ￿ A TUMOUR SELECTIVE PRODRUG 
ACTIVATION MECHANISM ?    
Richard Knox, Enact Pharma PLC, Porton Down, Salisbury, SP4 0JQ 
CB 1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] represents one of the very 
few examples of a compound that shows a real anti-tumour selectivity. 
Unfortunately, this is only seen in certain rat tumours. CB 1954 is a prodrug 
that is enzymatically activated to generate a difunctional agent, which can 
form DNA-DNA interstrand crosslinks. The bioactivation of CB 1954 in rat 
cells involves the aerobic reduction of its 4-nitro group to a 4-hydroxylamine 
by the enzyme NQO1 (DT-diaphorase). The human form of NQO1 
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tumours are insensitive to CB 1954. 
In view of the proven success of CB 1954 in the rat system, it would be 
highly desirable to re-create its anti-tumour activity in man. This has led to 
the development of CB 1954 analogues and other prodrugs activated by 
nitroreduction such as those based on a self-immolative activation 
mechanism. A gene therapy-based approach for targeting cancer cells and 
making them sensitive to CB 1954 and related compounds has been 
proposed. GDEPT (gene-directed enzyme prodrug therapy) has been used to 
express an E. coli nitroreductase in tumour cells and human tumour cells 
transduced to express this enzyme are very sensitive to prodrugs activated by 
nitroreduction. CB 1954 is in clinical trial for this application.   
Recently it has been show that a latent nitroreductase is present in some 
human tumours. This is NQO2 - an enzyme that requires for activity the non-
biogenic compound dihydronicotinamide riboside  (NRH) as a cosubstrate. 
When active, NQO2 is 3000 times more effective than human DT-diaphorase 
in the reduction of CB 1954.  NRH and reduced pyridinium derivatives that, 
like NRH, act as co-substrates for NQO2 produce a dramatic increase in the 
cytotoxicity of CB 1954 against human cell lines in vitro and its anti-tumour 
activity against certain human xenografts in vivo. NQO2 activity is 
substantially raised in tumour samples from colorectal and hepatoma patients 
(up to 14-fold). A phase I clinical trial of an NQO2 co-substrate with CB 
1954 is scheduled to start this year. 
S33 
POLYMER THERAPEUTICS AND THEIR COMBINATIONS FOR 
TUMOUR-SPECIFIC DELIVERY 
Ruth Duncan, Centre for Polymer Therapeutics, Welsh School of Pharmacy, 
Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK 
An increasing number of polymer-anticancer conjugates are entering Phase 
I/II clinical trials. Early results are very promising, especially as several of 
the polymeric carriers had never before been used in humans, and the 
optimum dosing schedule for such macromolecular prodrugs is still 
unknown. Consistently throughout these trials antitumour activity has been 
seen in chemotherapy refractory patients. The conjugates include; dextran-
doxorubicin, HPMA copolymer-doxorubicin PK1, FCE28068), HPMA 
copolymer-doxorubicin-galactosamine (PK2, FCE 28069), HPMA 
copolymer-paclitaxel (PNU166945), HPMA copolymer-camptothecin 
(MAG-CPT), polyglutamate-paclitaxel (CT-2103), HPMA copolymer-
platinate (Access Pharmaceuticals), and PEG-camptothecin (Enzon Inc). 
Three groups of compound have emerged. Conjugates that have failed 
because of toxicity of the carrier (dextran-doxorubicin); conjugates that have 
failed because of unacceptable toxicity of the conjugate (HPMA copolymer-
paclitaxel and HPMA copolymer-camptothecin probably due to inadequacy 
of the polymer-drug linkage, and finally those conjugates that have 
progressed into further Phase I/II trials. Two interesting Phase I studies are 
currently ongoing with the PGA-paclitaxel conjugate either as a single agent 
or combination with cisplatin at a dose of 75 mg/m
2 - the first combinations 
to be tested in man.  
So far, HPMA copolymer-doxorubicin-galactosamine designed to target liver 
and heptaocellular carcinoma via the asialoglycoprotein receptor is the only 
conjugate designed for receptor-mediated targeting. Most conjugates were 
designed to capitalise on passive tumour targeting by the EPR effect. In 
preclinical models this mechanism of targeting (due to hyperpermeable 
angiogenic vasculature) can give rise to 20 % dose/g in tumour tissue. Often 
the highest degree of targeting is seen in the smallest tumours giving hope for 
benefit in localisation in small micrometastases. Our current research is 
exploring several different therapeutic strategies that are designed to 
capitalise on improved tumour targeting by the EPR effect: (1) 
Lysosomotropic delivery Synthesis of conjugates containing novel, more 
potent drugs that also have novel mechanisms of action. (2) Intracytoplasmic 
delivery Use of bioresponsive polymers promote cytosolic access of genes 
and proteins. (3) Delivery of drug extracellullary Combination approaches 
such as polymer-directed enzyme prodrug therapy (PDEPT) or polymer-
directed enzyme liposomal therapy (PELT), and (4) Membrane-active 
polymer conjugates: Use of polymers as a platform for targeted delivery of 
antitumour agents that are active at the level of the plasma membrane.  
The current status of this field will be reviewed and future 
opportunities/challenges. addressed. 
S34 
DESIGN OF TISSUE-SPECIFIC OLIGOPEPTIDE PRODRUGS 
D J Mincher,Anticancer Drug Design and Delivery Research Group, School 
of Life Sciences, Napier University, Edinburgh, EH10 5DT, UK. 
The clinical usefulness of many low molecular mass antitumour compounds 
is restricted because of their narrow therapeutic index. Rational drug design 
of new cancer chemotherapeutics against identifiable molecular targets, that 
ideally should be causal factors in the pathogenesis of disease,  has so far 
been relatively unproductive at effecting cures for most malignancies; this 
approach is hampered by currently incomplete identification of all the 
molecular targets responsible for the majority of these cancers.  
An alternative approach is to capitalise on phenotypic rather than genetic 
differences between tumour cells and normal cycling tissues. Early examples 
of prodrugs of cytotoxins fail to meet the criteria for phenotypic targeting due 
to non-specific activation mechanisms, however, recent advances in the 
development of tumour-activated prodrugs have shown substantial 
improvements in antitumour activity;  promising, non-macromolecular 
examples will be reviewed. 
Synthetic organic-peptide conjugation chemistry is being applied to the 
design of tumour-activated prodrugs that transport and release the active 
agents in the tumour environment. The focus is the rational design of 
oligopeptide prodrug conjugates that are capable of harnessing ￿the dark side￿ 
of endogenous protease activity to achieve tissue-specific drug delivery and 
improve therapeutic index. 
S35 
THE ROLE OF CYP1B1 AS A TUMOUR SUPPRESSOR ENZYME 
G.A. Potter, Cancer Drug Discovery Group, School of Pharmacy, De 
Montfort University, Leicester LE1 9BH. 
A case is presented for the enzyme CYP1B1 functioning as a tumour 
suppressor enzyme which acts via the bioactivation of natural dietary 
compounds into growth inhibitory substances. The enzyme CYP1B1 is a 
human cytochrome P450 enzyme belonging to the CYP1 family, which 
comprises three member CYP1A1, CYP1A2, and CYP1B1. CYP1 family 
enzymes are known to metabolise xenobiotics and to activate procarcinogens 
into active carcinogens. CYP1B1 is of interest since it is highly expressed in 
many different types of human tumour (e.g. breast, colon, lung) but is not 
expressed in the normal tissue. This has led some researchers to conclude that 
CYP1B1 is involved in the cause of tumours due to its carcinogen activating 
ability. However this is a very simplistic view and does not explain why the 
CYP1B1 enzyme should be present in tumours in the first place, nor how it 
can be expressed in such a wide varity of tumours irrespective of their 
different oncogenic origins. We have developed an alternative hypothesis 
whereby CYP1B1 is functioning in an opposite sense, being there to destroy 
the tumour cells. Here we propose that CYP1B1 functions as a tumour 
suppressor enzyme through natural prodrug bioactivation. Preliminary 
evidence for this hypothesis has now been obtained and natural prodrugs with 
cancer preventative properties have been identified. 
1Murray, G.I., Taylor, M.C., McFadyen, M.C.E., McKay, J.A., Greenlee, 
W.F., Burke, M.D. & Melvin, W.T. Cancer Res., 57, 3026-3031, 1997 
2Potter, G.A., Patterson, L.H. & Burke, M.D. Aromatic hydroxylation 
activated (AHA) prodrugs. US Patent 6,214,886, 2001 
3G.A. Potter, L.H. Patterson, E. Wanogho, P.J. Perry, P.C. Butler, T. Ijaz, 
K.C. Ruparelia, J.H. Lamb, P.B. Farmer, L.A. Stanley, and M.D. Burke,  
Br. J. Cancer, 86, 774-778, 2002. 
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